Pharmacokinetic parameters for αCD20-IL-21 fusokine in vivo
| Variable . | IL-21 . | αCD20-IL-21 . |
|---|---|---|
| Half-life (T1/2), h | 0.238 ± 0.020 | 18.94 ± 0.413 |
| AUC0-96, ng-h/mL | 992 ± 447.34 | 10191 ± 388 |
| Vdarea, mL | 30.71 ± 2.59 | 5.3 ± 0.183 |
| MRT, h | 11.54 ± 0.04 | 26.11 ± 0.23 |
| CLarea, mL/h | 2.04 ± 0.09 | 0.198 ± 0.007 |
| Variable . | IL-21 . | αCD20-IL-21 . |
|---|---|---|
| Half-life (T1/2), h | 0.238 ± 0.020 | 18.94 ± 0.413 |
| AUC0-96, ng-h/mL | 992 ± 447.34 | 10191 ± 388 |
| Vdarea, mL | 30.71 ± 2.59 | 5.3 ± 0.183 |
| MRT, h | 11.54 ± 0.04 | 26.11 ± 0.23 |
| CLarea, mL/h | 2.04 ± 0.09 | 0.198 ± 0.007 |
To derive pharmacokinetic variables, the serum concentrations of human IL-21 were fit to a biexponential model (IL-21 and αCD20-IL-21). Data are mean ± SD. Serum IL-21 levels were measured using ELISA after intravenous injection in mice.
AUC, area under the curve; CL, clearance; MRT, mean resident time; Vd, volume of distribution.